Caricamento...
Ranibizumab Injection for Corneal Neovascularization Refractory to Bevacizumab Treatment
Vascular endothelial growth factor inhibitor is an emerging therapeutic modality for various ocular diseases with neovascularization (NV). However, for corneal NV, controversy remains regarding whether bevacizumab or ranibizumab is superior. A 32-year-old female diagnosed with herpetic keratoconjunc...
Salvato in:
| Autori principali: | , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
The Korean Ophthalmological Society
2014
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3958635/ https://ncbi.nlm.nih.gov/pubmed/24688262 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3341/kjo.2014.28.2.177 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|